Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC.

J Clin Oncol. 2009 Jun 10;27(17):2848-54. doi: 10.1200/JCO.2008.20.4552. Epub 2009 Apr 20.

2.
3.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG.

J Clin Oncol. 2003 Jun 1;21(11):2059-69.

PMID:
12775730
4.

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.

J Clin Oncol. 2004 Dec 1;22(23):4753-61. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570076
5.

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale.

J Clin Oncol. 2005 Aug 1;23(22):4866-75. Epub 2005 Jun 6.

PMID:
15939922
6.

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL.

Oncologist. 2001;6(1):81-91.

7.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest.

J Clin Oncol. 2007 May 1;25(13):1670-6.

PMID:
17470860
8.

The evolving role of oxaliplatin in the management of colorectal cancer.

de Gramont A, Schmoll HJ, Cervantes A, Tournigand C.

Colorectal Dis. 2003 Nov;5 Suppl 3:10-9. Review.

PMID:
23573556
9.
10.

FDA drug approval summaries: oxaliplatin.

Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R.

Oncologist. 2004;9(1):8-12.

11.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A.

J Clin Oncol. 2004 Jan 15;22(2):229-37. Epub 2003 Dec 2.

PMID:
14657227
12.

Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.

Liang XB, Hou SH, Li YP, Wang LC, Zhang X, Yang J.

Chin Med J (Engl). 2010 Nov;123(22):3314-8.

PMID:
21163137
13.

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA.

Cancer. 2004 Nov 15;101(10):2170-6.

14.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200.

J Clin Oncol. 2007 Apr 20;25(12):1539-44.

PMID:
17442997
15.

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.

Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Cartenì G, Leo SS, Catalano G, De Lena M, Comella G.

Ann Oncol. 2000 Oct;11(10):1323-33.

PMID:
11106123
16.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

17.

Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.

Simpson D, Dunn C, Curran M, Goa KL.

Drugs. 2003;63(19):2127-56. Review.

PMID:
12962525
18.

Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.

Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, Miwa K, Kawara K, Ichikawa W, Ando Y, Saji S, Sasaki Y.

Jpn J Clin Oncol. 2011 May;41(5):617-23. doi: 10.1093/jjco/hyr010. Epub 2011 Feb 9.

PMID:
21310730
19.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.

J Clin Oncol. 2007 Oct 20;25(30):4779-86.

PMID:
17947725
20.

[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].

Li J, Xu JM, Li J, Zhang XD, Bai Y, Chu YP, Wang YH, Liu DQ, Jin ML, Shen L.

Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):225-7. Chinese.

PMID:
18756942

Supplemental Content

Support Center